Wali M, Harrison R F, Gow P J, Mutimer D
Liver and Hepatobiliary Unit, Queen Elizabeth Hospital and Department of Medicine, University of Birmingham, Birmingham, UK .
Gut. 2002 Aug;51(2):248-52. doi: 10.1136/gut.51.2.248.
Cirrhosis with liver failure due to hepatitis C virus (HCV) infection is the most common indication for liver transplantation (LT). Reinfection of the transplanted liver by HCV is inevitable, and aggressive hepatitis with accelerated progression to graft cirrhosis may be observed. Of concern, recent reports suggest that the outcome of LT for HCV may have deteriorated in recent years. Determinants of rate of progression to cirrhosis in the immunocompetent non-transplant patient are well defined, and the most powerful determinant is patient age at the time of infection. Following LT for HCV, recipient age does not affect outcome of HCV reinfection. However, the impact of donor age on graft fibrosis progression rate following LT has not been examined.
We have examined post-transplant biopsies to assess histological activity, including fibrosis stage (scored 0-6 units, 6 representing established cirrhosis), and to calculate fibrosis progression rates in 101 post-transplant specimens from 56 HCV infected LT patients. Univariate and multivariate analyses examined the impact of parameters including recipient and donor age and sex on fibrosis progression rate, and on predicted time to cirrhosis.
For the cohort, median fibrosis progression rate was 0.78 units/year, and median interval from transplantation to development of cirrhosis was 7.7 years. In multivariate analysis, donor age (not recipient age) was a powerful determinant (p=0.02) of fibrosis progression rate. When the liver donor was younger than 40 years, median progression rate was 0.6 units/year and interval to cirrhosis was 10 years. When the donor was aged 50 years or more, median progression rate was 2.7 units/year and interval to cirrhosis only 2.2 years. During the observation period there has been a significant increase in donor age (p=0.01) but date of transplantation per se is not a determinant of progression rate when included in multivariate analyses.
Donor age has a major influence on graft outcome following transplantation for HCV. The changing organ donor profile will affect the long term results of LT for HCV. These observations have important implications for donor liver allocation.
丙型肝炎病毒(HCV)感染所致肝硬化伴肝衰竭是肝移植(LT)最常见的适应证。移植肝被HCV再次感染不可避免,可能会出现侵袭性肝炎并加速发展为移植肝肝硬化。令人担忧的是,最近的报告表明,近年来HCV肝移植的结果可能有所恶化。免疫功能正常的非移植患者肝硬化进展速度的决定因素已明确,最有力的决定因素是感染时的患者年龄。HCV肝移植后,受者年龄不影响HCV再次感染的结果。然而,供者年龄对肝移植后移植肝纤维化进展速度的影响尚未得到研究。
我们检查了移植后的活检组织,以评估组织学活性,包括纤维化阶段(评分为0 - 6分,6分代表已形成肝硬化),并计算了56例HCV感染肝移植患者的101份移植后标本的纤维化进展速度。单因素和多因素分析研究了包括受者和供者年龄及性别等参数对纤维化进展速度以及预测肝硬化发生时间的影响。
对于该队列,纤维化进展速度的中位数为0.78分/年,从移植到发生肝硬化的中位间隔时间为7.7年。在多因素分析中,供者年龄(而非受者年龄)是纤维化进展速度的有力决定因素(p = 0.02)。当肝脏供者年龄小于40岁时,进展速度中位数为0.6分/年,发生肝硬化的间隔时间为10年。当供者年龄为50岁及以上时,进展速度中位数为2.7分/年,发生肝硬化的间隔时间仅为2.2年。在观察期内,供者年龄有显著增加(p = 0.01),但在多因素分析中,移植日期本身并非进展速度的决定因素。
供者年龄对HCV移植后的移植肝结局有重大影响。不断变化的器官供者情况将影响HCV肝移植的长期结果。这些观察结果对供肝分配具有重要意义。